Qyuns Therapeutics Co., Ltd. (Qyuns/the “Company”, Stock Code: 2509.HK) is pleased to announce that the long-acting bispecific antibody QX027N injection independently developed by the Company has obtained clinical trial approvals from the Center for Drug Evaluation of the National Medical Products Administration (Acceptance Nos.: CXSL2500757, CXSL2500758), intended for the treatment of asthma and atopic dermatitis. The clinical approvals of this drug candidate signify that the Company’s innovative bispecific antibody pipeline for autoimmune and allergic diseases has officially entered the clinical stage.

Screenshot of the CDE official website

Mr. Qiu Jiwan, Founder, Chairman of the Board and General Manager of Qyuns, stated that the clinical approvals of QX027N represent a significant milestone in the Company’s bispecific antibody pipeline, marking further progress in the synergistic development across respiratory and dermatological disease areas. To address the unmet clinical needs of hundreds of millions of patients with asthma and atopic dermatitis worldwide, the Company will continue to advance the research, development and clinical translation of innovative therapies, thereby providing patients with more effective, safer and more convenient treatment options.

STATEMENT

*The purpose of this news is to share cutting-edge information on the research and development work of the company (or its partners), not for advertising purposes, and not to recommend any drugs and/or indications. If you have any related diseases or medication needs, please consult a professional physician. *The press release may contain certain forward-looking statements that are inherently risky and uncertain. When using "expectation", "belief", "forecast", "expectation", "plan", "intention" and other similar words, all statements related to the company are forward-looking statements. The company is not obligated to keep these predictive statements updated. These forward-looking statements are based on the existing views, assumptions, expectations, estimates, forecasts and understandings of the company's management on future affairs when making statements, and are not a guarantee for future development or a reliable indicator of future performance. It is hereby expressly cautioned that you should not rely on any forward-looking statements. Forward looking statements are subject to various risks, uncertainties and other factors (including but not limited to general market conditions, regulatory changes, geopolitical tensions or data restrictions and changes), some of which are beyond the company's control and difficult to predict. Therefore, the actual results may be significantly different from the information contained in the forward-looking statements due to future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The company, its directors and employee agents do not assume any obligation to update, amend or supplement such forward-looking statements and any liability arising from the failure or inaccuracy of any forward-looking statements.

Disclaimer

*This news release is intended to share the latest progress updates on the R&D efforts of the Company (or its partners) and is not for advertising purposes. It does not constitute a recommendation for any drugs and/or indications. For any related diseases or medication needs, please consult a qualified healthcare professional.

*This news release may contain certain forward-looking statements, which are inherently subject to significant risks and uncertainties. When words such as "anticipate," "believe," "predict," "expect," "plan," "intend" and other similar expressions are used, insofar as they relate to the Company, they shall be deemed to be forward-looking statements. The Company has no obligation to continuously update these predictive statements. These forward-looking statements are based on the current views, assumptions, expectations, estimates, projections and understandings of the Company’s management regarding future events at the time of making such statements. They do not constitute guarantees of future developments nor reliable indicators of future performance. We hereby explicitly caution you that you should not rely on any forward-looking statements. Forward-looking statements are subject to various risks, uncertainties and other factors (including but not limited to general market conditions, regulatory changes, geopolitical tensions, or data limitations and changes), some of which are beyond the Company’s control and difficult to predict. Therefore, due to future changes and developments in our business, competitive environment, political, economic, legal and social conditions, actual results may differ materially from the information contained in the forward-looking statements. The Company, its directors and employee agents shall not be liable for any obligation to update, revise or supplement such forward-looking statements, nor for any liability arising from the failure or inaccuracy of any forward-looking statements.